ATE404170T1 - Subkutanes verabreichungssystem, verfahren zur herstellung desselben und verwendung zur behandlung von mangelerscheinung des cholinergen nervensystems - Google Patents

Subkutanes verabreichungssystem, verfahren zur herstellung desselben und verwendung zur behandlung von mangelerscheinung des cholinergen nervensystems

Info

Publication number
ATE404170T1
ATE404170T1 AT04720662T AT04720662T ATE404170T1 AT E404170 T1 ATE404170 T1 AT E404170T1 AT 04720662 T AT04720662 T AT 04720662T AT 04720662 T AT04720662 T AT 04720662T AT E404170 T1 ATE404170 T1 AT E404170T1
Authority
AT
Austria
Prior art keywords
group
producing
treatment
same
subcutaneous administration
Prior art date
Application number
AT04720662T
Other languages
English (en)
Inventor
Rolland-Yves Mauvernay
Herve Porchet
Pietro Scalfaro
Frederic Heimgartner
Bertrand Ducrey
Francois Pfefferle
Sergio Capancioni
Cormick Mark Mc
Original Assignee
Debio Rech Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debio Rech Pharma Sa filed Critical Debio Rech Pharma Sa
Application granted granted Critical
Publication of ATE404170T1 publication Critical patent/ATE404170T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thermotherapy And Cooling Therapy Devices (AREA)
  • Percussion Or Vibration Massage (AREA)
AT04720662T 2003-03-14 2004-03-15 Subkutanes verabreichungssystem, verfahren zur herstellung desselben und verwendung zur behandlung von mangelerscheinung des cholinergen nervensystems ATE404170T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB0300942 2003-03-14
IB0304945 2003-11-05

Publications (1)

Publication Number Publication Date
ATE404170T1 true ATE404170T1 (de) 2008-08-15

Family

ID=32992641

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04720662T ATE404170T1 (de) 2003-03-14 2004-03-15 Subkutanes verabreichungssystem, verfahren zur herstellung desselben und verwendung zur behandlung von mangelerscheinung des cholinergen nervensystems

Country Status (24)

Country Link
US (1) US20070059369A1 (de)
EP (2) EP1977735A1 (de)
JP (1) JP2006520378A (de)
KR (1) KR20060023111A (de)
AT (1) ATE404170T1 (de)
AU (1) AU2004218896B2 (de)
BR (1) BRPI0407818A (de)
CA (1) CA2518883A1 (de)
CY (1) CY1108482T1 (de)
DE (1) DE602004015744D1 (de)
DK (1) DK1603532T3 (de)
EA (1) EA011169B1 (de)
ES (1) ES2312981T3 (de)
HK (1) HK1089085A1 (de)
IL (1) IL170759A (de)
IS (1) IS8067A (de)
MX (1) MXPA05009626A (de)
NO (1) NO20054258L (de)
NZ (1) NZ542459A (de)
PL (1) PL1603532T3 (de)
PT (1) PT1603532E (de)
SI (1) SI1603532T1 (de)
UA (1) UA82226C2 (de)
WO (1) WO2004080436A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2575988C (en) 2004-08-04 2014-02-18 Brookwood Pharmaceuticals, Inc. Methods for manufacturing delivery devices and devices thereof
US8124601B2 (en) * 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
CA2709712C (en) 2007-12-20 2016-05-10 Surmodics Pharmaceuticals, Inc. Process for preparing microparticles having a low residual solvent volume
US8956636B2 (en) * 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Methods and compositions for treating postoperative pain comprosing ketorolac
EP2560623A1 (de) 2010-04-22 2013-02-27 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Orale retard-formulierung von huperzin a
US20150191430A1 (en) * 2012-05-18 2015-07-09 Insero Health Inc. Conjugates of huperzine and analogs thereof
KR101811797B1 (ko) * 2013-04-03 2017-12-22 동국제약 주식회사 도네페질을 포함하는 비경구투여용 약제학적 조성물
JP7111375B2 (ja) * 2017-10-19 2022-08-02 株式会社佐藤園 学習記憶能力増強組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106979A (en) * 1989-02-21 1992-04-21 University Of Pittsburgh Method for the synthesis of huperzine A and analogs thereof and compounds useful therein
CN1125725A (zh) 1994-12-28 1996-07-03 中国科学院上海药物研究所 一类海克林碱衍生物及它的用途
FR2756493B1 (fr) * 1996-12-02 2001-04-13 Delab Dispositif d'administration locale de formulations solides ou semi-solides
US6352715B1 (en) 1998-02-19 2002-03-05 Sagittarius Life Science Corp Transdermal rate-controlled delivery of Huperzine A for treatment of alzheimer's disease
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
CN1279065A (zh) 1999-07-06 2001-01-10 青岛科达生物工程有限公司 一种治疗记忆障碍和老年痴呆的药物组合物
CN1194688C (zh) 2001-07-03 2005-03-30 山东绿叶制药股份有限公司 石杉碱甲及其衍生物或其盐的注射用缓释微球及其制备方法
CN1383824A (zh) 2002-05-21 2002-12-11 浙江省医学科学院 石杉碱鼻腔给药制剂

Also Published As

Publication number Publication date
PL1603532T3 (pl) 2009-02-27
HK1089085A1 (en) 2006-11-24
EP1977735A1 (de) 2008-10-08
ES2312981T3 (es) 2009-03-01
NO20054258L (no) 2005-11-24
IS8067A (is) 2005-10-11
MXPA05009626A (es) 2005-10-18
CA2518883A1 (en) 2004-09-23
UA82226C2 (uk) 2008-03-25
WO2004080436A1 (en) 2004-09-23
NO20054258D0 (no) 2005-09-15
SI1603532T1 (sl) 2009-02-28
IL170759A (en) 2010-06-16
JP2006520378A (ja) 2006-09-07
PT1603532E (pt) 2008-11-20
US20070059369A1 (en) 2007-03-15
CY1108482T1 (el) 2014-04-09
KR20060023111A (ko) 2006-03-13
EA011169B1 (ru) 2009-02-27
BRPI0407818A (pt) 2006-02-14
DE602004015744D1 (de) 2008-09-25
EA200501433A1 (ru) 2006-02-24
EP1603532A1 (de) 2005-12-14
EP1603532B1 (de) 2008-08-13
DK1603532T3 (da) 2008-12-08
AU2004218896A1 (en) 2004-09-23
AU2004218896B2 (en) 2010-04-01
NZ542459A (en) 2008-12-24

Similar Documents

Publication Publication Date Title
CY1108482T1 (el) Συστημα υποδοριας διανομης, μεθοδος παρασκευης του και χρηση του για την αγωγη διαταραχων xολινεργικης ανεπαρκειας
BR0215429A (pt) Composto de fórmula i e seus usos, métodos de inibição da atividade e método de inibição da ativação de um receptor de monoamina, métodos de tratamento, método de identificação de polimorfismo genético e método de identificação de paciente
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
TR200201430T2 (tr) Antiproliferatif maddeler olarak faydalı yeni benzoimidazol türevleri.
ATE267798T1 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
HK1080764A1 (en) Implant for transport and release for pharmacologically active agents as well as a process for producing the same
ATE212834T1 (de) 2,2-dichloralkancarbonsäuren, verfahren zu ihrer herstellung diese enthaltende arzneimittel, und ihre verwendung zur behandlung der insulinresistenz
DE60203847D1 (de) Verbindungen enthaltend S-Tofisopam sowie Verwendung dieser Verbindungen zur Herstellung eines Medikamentes zur Behandlung oder Prophylaxe von Krämpfen und Anfällen
ATE252389T1 (de) Ein arzneimittel zur behandlung von fettleibigkeit und verbesserung des lipidmetabolismus
ATE369348T1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
ID29025A (id) Fenilalkenoilguanidina-fenilalkenoilguanidina yang disubstitusi asam empedu, proses pembuatannya, penggunaannya sebagai obat atau diaknostik dan obat-obat yang mengandungnya
ATE85334T1 (de) Bisphenylalkylpiperazin-derivate, verfahren zur herstellung und arzneimittelzubereitung.
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
ATE294582T1 (de) Verwendung von alpha-1-adrenorezeptor- antagonisten zur herstellung eines medikaments für die vorbeugung und die behandlung von krebs
ATE417831T1 (de) Ceramid ähnliche verbindungen, verfahren zu deren herstellung und deren verwendung als antitumormittel
DE69930624D1 (de) Arzneimittel für hinterstrangataxie und zusammensetzung zur behandlung von hinterstrangataxie
DE69619868D1 (de) Piperazinylalkylthiopyrimidin derivate, diese enthaltende pharmazeutische zusammensetzungen und verfahren zu deren herstellung
DE50108711D1 (de) Verwendung von substituierten 6-dimethylaminomethyl-1-phenyl-cyclohexanverbindungen zur therapie der harninkontinenz
ATE300311T1 (de) Vorbereitung eines medikaments zur behandlung von refluxösophagitis
HUP9904578A2 (hu) Xanomelin alkalmazása bipoláris depresszió kezelésére szolgáló gyógyszerkészítmények előállítására
BR0210407A (pt) Composto, composição farmacêutica, uso de um composto e método de tratamento de um distúrbio ou de uma doença de corpo animal vivo, incluindo um humano
DE69902537D1 (de) Eine verbindung, wf002, ein verfahren zu ihrer herstellung und ihre verwendung
UA36167A (uk) Спосіб лікування панкреатиту

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1603532

Country of ref document: EP

REN Ceased due to non-payment of the annual fee